Cargando…

Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection

OBJECTIVES: SARS-CoV-2 exhibits tropism for the gastrointestinal tract; however, lesions in enterocytes and their correlation with disease severity and patient prognosis are still unknown. METHODS: SARS-CoV-2 patients were enrolled in 5 medical centres in São Paulo, Brazil and their clinical charact...

Descripción completa

Detalles Bibliográficos
Autores principales: Saia, Rafael Simone, Giusti, Humberto, Luis-Silva, Fábio, Pedroso, Karina de Jesus Bonicenha, Auxiliadora-Martins, Maria, Morejón, Karen Mirna Loro, Degiovani, Augusto Marcussi, Cadelca, Márcia Regina, Basile-Filho, Anibal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479553/
https://www.ncbi.nlm.nih.gov/pubmed/34597762
http://dx.doi.org/10.1016/j.ijid.2021.09.051
_version_ 1784576284064481280
author Saia, Rafael Simone
Giusti, Humberto
Luis-Silva, Fábio
Pedroso, Karina de Jesus Bonicenha
Auxiliadora-Martins, Maria
Morejón, Karen Mirna Loro
Degiovani, Augusto Marcussi
Cadelca, Márcia Regina
Basile-Filho, Anibal
author_facet Saia, Rafael Simone
Giusti, Humberto
Luis-Silva, Fábio
Pedroso, Karina de Jesus Bonicenha
Auxiliadora-Martins, Maria
Morejón, Karen Mirna Loro
Degiovani, Augusto Marcussi
Cadelca, Márcia Regina
Basile-Filho, Anibal
author_sort Saia, Rafael Simone
collection PubMed
description OBJECTIVES: SARS-CoV-2 exhibits tropism for the gastrointestinal tract; however, lesions in enterocytes and their correlation with disease severity and patient prognosis are still unknown. METHODS: SARS-CoV-2 patients were enrolled in 5 medical centres in São Paulo, Brazil and their clinical characteristics and laboratory findings recorded. At admission, day 7 and day 14 of hospitalisation, plasma and urine samples were collected, and cytokine levels and intestinal fatty acid-binding protein (I-FABP) concentrations measured. RESULTS: COVID-19 patients displayed ≈48-, 74- and 125-fold increased urinary I-FABP levels at admission (n=283; P<0.001), day 7 (n=142; P<0.01) and day 14 (n=75; P<0.01) of hospitalisation. Critically ill patients and nonsurvivors showed higher I-FABP concentrations compared with patients with less severe illness. At admission, infected patients demonstrated enhanced production of plasma interferon (IFN)-γ and interleukin (IL)-6. The receiver operating characteristic curve suggested I-FABP as a biomarker for COVID-19 disease severity at admission (P<0.0001; Youden index=6.89; area under the curve=0.699). Patients with I-FABP ≥6.89 showed higher IL-6 and C-reactive protein levels (P<0.001) at admission and had a prolonged length of hospital stay. CONCLUSIONS: Our findings revealed damage to enterocytes in SARS-CoV-2 infection, which is associated with illness severity, poor prognosis and exacerbated inflammatory response.
format Online
Article
Text
id pubmed-8479553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-84795532021-09-29 Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection Saia, Rafael Simone Giusti, Humberto Luis-Silva, Fábio Pedroso, Karina de Jesus Bonicenha Auxiliadora-Martins, Maria Morejón, Karen Mirna Loro Degiovani, Augusto Marcussi Cadelca, Márcia Regina Basile-Filho, Anibal Int J Infect Dis Short Communication OBJECTIVES: SARS-CoV-2 exhibits tropism for the gastrointestinal tract; however, lesions in enterocytes and their correlation with disease severity and patient prognosis are still unknown. METHODS: SARS-CoV-2 patients were enrolled in 5 medical centres in São Paulo, Brazil and their clinical characteristics and laboratory findings recorded. At admission, day 7 and day 14 of hospitalisation, plasma and urine samples were collected, and cytokine levels and intestinal fatty acid-binding protein (I-FABP) concentrations measured. RESULTS: COVID-19 patients displayed ≈48-, 74- and 125-fold increased urinary I-FABP levels at admission (n=283; P<0.001), day 7 (n=142; P<0.01) and day 14 (n=75; P<0.01) of hospitalisation. Critically ill patients and nonsurvivors showed higher I-FABP concentrations compared with patients with less severe illness. At admission, infected patients demonstrated enhanced production of plasma interferon (IFN)-γ and interleukin (IL)-6. The receiver operating characteristic curve suggested I-FABP as a biomarker for COVID-19 disease severity at admission (P<0.0001; Youden index=6.89; area under the curve=0.699). Patients with I-FABP ≥6.89 showed higher IL-6 and C-reactive protein levels (P<0.001) at admission and had a prolonged length of hospital stay. CONCLUSIONS: Our findings revealed damage to enterocytes in SARS-CoV-2 infection, which is associated with illness severity, poor prognosis and exacerbated inflammatory response. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-12 2021-09-28 /pmc/articles/PMC8479553/ /pubmed/34597762 http://dx.doi.org/10.1016/j.ijid.2021.09.051 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Saia, Rafael Simone
Giusti, Humberto
Luis-Silva, Fábio
Pedroso, Karina de Jesus Bonicenha
Auxiliadora-Martins, Maria
Morejón, Karen Mirna Loro
Degiovani, Augusto Marcussi
Cadelca, Márcia Regina
Basile-Filho, Anibal
Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
title Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
title_full Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
title_fullStr Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
title_full_unstemmed Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
title_short Clinical investigation of intestinal fatty acid-binding protein (I-FABP) as a biomarker of SARS-CoV-2 infection
title_sort clinical investigation of intestinal fatty acid-binding protein (i-fabp) as a biomarker of sars-cov-2 infection
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479553/
https://www.ncbi.nlm.nih.gov/pubmed/34597762
http://dx.doi.org/10.1016/j.ijid.2021.09.051
work_keys_str_mv AT saiarafaelsimone clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT giustihumberto clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT luissilvafabio clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT pedrosokarinadejesusbonicenha clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT auxiliadoramartinsmaria clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT morejonkarenmirnaloro clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT degiovaniaugustomarcussi clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT cadelcamarciaregina clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection
AT basilefilhoanibal clinicalinvestigationofintestinalfattyacidbindingproteinifabpasabiomarkerofsarscov2infection